{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015599","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.933419+00:00","generated_at":"2026-06-15T16:28:15.929648+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Qualigen Therapeutics regains Nasdaq compliance after filing overdue 10-K","bullets":["Received delisting notice on April 20, 2023 for late filing of 2022 Form 10-K.","Filed the delinquent Form 10-K on May 2, 2023.","On May 4, 2023, Nasdaq confirmed compliance with Listing Rule 5250(c)(1); matter closed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015599","json":"https://secwatch.observer/filing/0001493152-23-015599.json","markdown":"https://secwatch.observer/filing/0001493152-23-015599.md","text":"https://secwatch.observer/filing/0001493152-23-015599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/0001493152-23-015599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:28:15.929648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41d4ebf7f123c70577ad27b00537359af5066129","claim":"AIxCrypto Holdings, Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"May 4, 2023 that it had regained compliance with Nasdaq’s listing rule 5250(c)(1) as a result thereof and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: May 5, 2023 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/0001493152-23-015599-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}